Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Ludwig Kappos; David Bates; Gilles Edan; Mefkûre Eraksoy; Antonio Garcia-Merino; Nikolaos Grigoriadis; Hans-Peter Hartung; Eva Havrdová; Jan Hillert; Reinhard Hohlfeld; Marcelo Kremenchutzky; Olivier Lyon-Caen; Ariel Miller; Carlo Pozzilli; Mads Ravnborg; Takahiko Saida; Christian Sindic; Karl Vass; David B Clifford; Stephen Hauser; Eugene O Major; Paul W O'Connor; Howard L Weiner; Michel Clanet; Ralf Gold; Hans H Hirsch; Ernst-Wilhelm Radü; Per Soelberg Sørensen; John King

doi:http://dx.doi.org/10.1016/S1474-4422(11)70149-1

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Ludwig Kappos, David Bates, Gilles Edan, Mefkûre Eraksoy, Antonio Garcia-Merino, Nikolaos Grigoriadis, Hans-Peter Hartung, Eva Havrdová, Jan Hillert, Reinhard Hohlfeld, Marcelo Kremenchutzky, Olivier Lyon-Caen, Ariel Miller, Carlo Pozzilli, Mads Ravnborg, Takahiko Saida, Christian Sindic, Karl Vass, David B Clifford, Stephen HauserEugene O Major, Paul W O'Connor, Howard L Weiner, Michel Clanet, Ralf Gold, Hans H Hirsch, Ernst-Wilhelm Radü, Per Soelberg Sørensen, John King

Institut for Klinisk Medicin

225 Citationer (Scopus)

Abstract

Natalizumab, a highly specific α4-integrin antagonist, is approved for treatment of patients with active relapsing-remitting multiple sclerosis (RRMS). It is generally recommended for individuals who have not responded to a currently available first-line disease-modifying therapy or who have very active disease. The expected benefits of natalizumab treatment have to be weighed against risks, especially the rare but serious adverse event of progressive multifocal leukoencephalopathy. In this Review, we revisit and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommendations.

Originalsprog	Engelsk
Tidsskrift	Lancet Neurology
Vol/bind	10
Udgave nummer	8
Sider (fra-til)	745-58
Antal sider	14
ISSN	1474-4422
DOI	https://doi.org/10.1016/S1474-4422(11)70149-1
Status	Udgivet - aug. 2011

Adgang til dokumentet

http://dx.doi.org/10.1016/S1474-4422(11)70149-1

Citationsformater

Kappos, L., Bates, D., Edan, G., Eraksoy, M., Garcia-Merino, A., Grigoriadis, N., Hartung, H-P., Havrdová, E., Hillert, J., Hohlfeld, R., Kremenchutzky, M., Lyon-Caen, O., Miller, A., Pozzilli, C., Ravnborg, M., Saida, T., Sindic, C., Vass, K., Clifford, D. B., ... King, J. (2011). Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurology, 10(8), 745-58. https://doi.org/10.1016/S1474-4422(11)70149-1

Kappos, L, Bates, D, Edan, G, Eraksoy, M, Garcia-Merino, A, Grigoriadis, N, Hartung, H-P, Havrdová, E, Hillert, J, Hohlfeld, R, Kremenchutzky, M, Lyon-Caen, O, Miller, A, Pozzilli, C, Ravnborg, M, Saida, T, Sindic, C, Vass, K, Clifford, DB, Hauser, S, Major, EO, O'Connor, PW, Weiner, HL, Clanet, M, Gold, R, Hirsch, HH, Radü, E-W, Sørensen, PS & King, J 2011, 'Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring', Lancet Neurology, bind 10, nr. 8, s. 745-58. https://doi.org/10.1016/S1474-4422(11)70149-1

@article{f7e21ec16da948d5a566e81e04e75a3c,

title = "Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring",

abstract = "Natalizumab, a highly specific α4-integrin antagonist, is approved for treatment of patients with active relapsing-remitting multiple sclerosis (RRMS). It is generally recommended for individuals who have not responded to a currently available first-line disease-modifying therapy or who have very active disease. The expected benefits of natalizumab treatment have to be weighed against risks, especially the rare but serious adverse event of progressive multifocal leukoencephalopathy. In this Review, we revisit and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommendations.",

author = "Ludwig Kappos and David Bates and Gilles Edan and Mefk{\^u}re Eraksoy and Antonio Garcia-Merino and Nikolaos Grigoriadis and Hans-Peter Hartung and Eva Havrdov{\'a} and Jan Hillert and Reinhard Hohlfeld and Marcelo Kremenchutzky and Olivier Lyon-Caen and Ariel Miller and Carlo Pozzilli and Mads Ravnborg and Takahiko Saida and Christian Sindic and Karl Vass and Clifford, {David B} and Stephen Hauser and Major, {Eugene O} and O'Connor, {Paul W} and Weiner, {Howard L} and Michel Clanet and Ralf Gold and Hirsch, {Hans H} and Ernst-Wilhelm Rad{\"u} and S{\o}rensen, {Per Soelberg} and John King",

year = "2011",

month = aug,

doi = "http://dx.doi.org/10.1016/S1474-4422(11)70149-1",

language = "English",

volume = "10",

pages = "745--58",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "TheLancet Publishing Group",

number = "8",

}

TY - JOUR

T1 - Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

AU - Kappos, Ludwig

AU - Bates, David

AU - Edan, Gilles

AU - Eraksoy, Mefkûre

AU - Garcia-Merino, Antonio

AU - Grigoriadis, Nikolaos

AU - Hartung, Hans-Peter

AU - Havrdová, Eva

AU - Hillert, Jan

AU - Hohlfeld, Reinhard

AU - Kremenchutzky, Marcelo

AU - Lyon-Caen, Olivier

AU - Miller, Ariel

AU - Pozzilli, Carlo

AU - Ravnborg, Mads

AU - Saida, Takahiko

AU - Sindic, Christian

AU - Vass, Karl

AU - Clifford, David B

AU - Hauser, Stephen

AU - Major, Eugene O

AU - O'Connor, Paul W

AU - Weiner, Howard L

AU - Clanet, Michel

AU - Gold, Ralf

AU - Hirsch, Hans H

AU - Radü, Ernst-Wilhelm

AU - Sørensen, Per Soelberg

AU - King, John

PY - 2011/8

Y1 - 2011/8

N2 - Natalizumab, a highly specific α4-integrin antagonist, is approved for treatment of patients with active relapsing-remitting multiple sclerosis (RRMS). It is generally recommended for individuals who have not responded to a currently available first-line disease-modifying therapy or who have very active disease. The expected benefits of natalizumab treatment have to be weighed against risks, especially the rare but serious adverse event of progressive multifocal leukoencephalopathy. In this Review, we revisit and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommendations.

AB - Natalizumab, a highly specific α4-integrin antagonist, is approved for treatment of patients with active relapsing-remitting multiple sclerosis (RRMS). It is generally recommended for individuals who have not responded to a currently available first-line disease-modifying therapy or who have very active disease. The expected benefits of natalizumab treatment have to be weighed against risks, especially the rare but serious adverse event of progressive multifocal leukoencephalopathy. In this Review, we revisit and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommendations.

U2 - http://dx.doi.org/10.1016/S1474-4422(11)70149-1

DO - http://dx.doi.org/10.1016/S1474-4422(11)70149-1

M3 - Journal article

SN - 1474-4422

VL - 10

SP - 745

EP - 758

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 8

ER -

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater